BACKGROUND: In a phase III trial, 3-weekly capecitabine (1250 mg/m(2) twice daily days 1-14) plus docetaxel (75 mg/m(2) day 1) demonstrated significantly superior overall survival to 3-weekly docetaxel (100 mg/m(2) day 1). We report a retrospective analysis of the impact of capecitabine/docetaxel dose reduction on safety and efficacy. PATIENTS AND METHODS: Safety and efficacy data were analyzed retrospectively according to the actual doses of capecitabine and docetaxel administered. RESULTS: More patients receiving capecitabine/docetaxel (65%) had dose reductions for adverse events than docetaxel alone (35%). In most patients requiring dose reduction with the combination (80%), capecitabine and docetaxel were simultaneously reduced to 950 mg/m(2) and 55 mg/m(2), respectively. Subsequently, there were fewer cycles (17%) with grade 3/4 adverse events than with the full doses (34%). Time to progression and overall survival appeared to be similar in patients starting the second cycle with reduced doses of capecitabine/docetaxel and those who continued to receive full doses of capecitabine/docetaxel for at least the first four cycles. CONCLUSIONS:Capecitabine/docetaxel dosing flexibility allows management of side-effects without compromising efficacy. This retrospective analysis, as well as multiple phase II studies of taxanes with reduced-dose capecitabine, shows that reducing the starting dose of capecitabine with docetaxel is a reasonable strategy for the treatment of patients with metastatic breast cancer. In addition, reducing the dose of both agents may be appropriate.
RCT Entities:
BACKGROUND: In a phase III trial, 3-weekly capecitabine (1250 mg/m(2) twice daily days 1-14) plus docetaxel (75 mg/m(2) day 1) demonstrated significantly superior overall survival to 3-weekly docetaxel (100 mg/m(2) day 1). We report a retrospective analysis of the impact of capecitabine/docetaxel dose reduction on safety and efficacy. PATIENTS AND METHODS: Safety and efficacy data were analyzed retrospectively according to the actual doses of capecitabine and docetaxel administered. RESULTS: More patients receiving capecitabine/docetaxel (65%) had dose reductions for adverse events than docetaxel alone (35%). In most patients requiring dose reduction with the combination (80%), capecitabine and docetaxel were simultaneously reduced to 950 mg/m(2) and 55 mg/m(2), respectively. Subsequently, there were fewer cycles (17%) with grade 3/4 adverse events than with the full doses (34%). Time to progression and overall survival appeared to be similar in patients starting the second cycle with reduced doses of capecitabine/docetaxel and those who continued to receive full doses of capecitabine/docetaxel for at least the first four cycles. CONCLUSIONS:Capecitabine/docetaxel dosing flexibility allows management of side-effects without compromising efficacy. This retrospective analysis, as well as multiple phase II studies of taxanes with reduced-dose capecitabine, shows that reducing the starting dose of capecitabine with docetaxel is a reasonable strategy for the treatment of patients with metastatic breast cancer. In addition, reducing the dose of both agents may be appropriate.
Authors: Lawrence G Lum; Archana Thakur; Zaid Al-Kadhimi; Gerald A Colvin; Francis J Cummings; Robert D Legare; Don S Dizon; Nicola Kouttab; Abby Maizel; William Colaiace; Qin Liu; Ritesh Rathore Journal: Clin Cancer Res Date: 2015-02-16 Impact factor: 12.531
Authors: Ann H Partridge; R Bryan Rumble; Lisa A Carey; Steven E Come; Nancy E Davidson; Angelo Di Leo; Julie Gralow; Gabriel N Hortobagyi; Beverly Moy; Douglas Yee; Shelley B Brundage; Michael A Danso; Maggie Wilcox; Ian E Smith Journal: J Clin Oncol Date: 2014-09-02 Impact factor: 44.544
Authors: E A Perez; D W Hillman; T Dentchev; N A Le-Lindqwister; L H Geeraerts; T R Fitch; H Liu; D L Graham; S P Kahanic; H M Gross; T A Patel; F M Palmieri; A C Dueck Journal: Ann Oncol Date: 2009-11-09 Impact factor: 32.976
Authors: Yago Nieto; José Manuel Aramendía; Jaime Espinós; Susana De la Cruz; Oscar Fernández-Hidalgo; Marta Santisteban; Leyre Arbea; Javier Aristu; Rafael Martínez-Monge; Marta Moreno; Luis Pina; Josu Sola; Gerardo Zornoza; Fernando Martínez Regueira Journal: Cancer Chemother Pharmacol Date: 2009-06-14 Impact factor: 3.333
Authors: Siao-Nge Hoon; Peter Kh Lau; Alison M White; Max K Bulsara; Patricia D Banks; Andrew D Redfern Journal: Cochrane Database Syst Rev Date: 2021-05-26
Authors: S Ohno; L W C Chow; N Sato; N Masuda; H Sasano; F Takahashi; H Bando; H Iwata; T Morimoto; S Kamigaki; T Nakayama; S Nakamura; K Kuroi; K Aogi; M Kashiwaba; H Yamashita; K Hisamatsu; Y Ito; Y Yamamoto; T Ueno; E Fakhrejahani; N Yoshida; M Toi Journal: Breast Cancer Res Treat Date: 2013-11 Impact factor: 4.872
Authors: Fatima Cardoso; Philippe L Bedard; Eric P Winer; Olivia Pagani; Elzbieta Senkus-Konefka; Lesley J Fallowfield; Stella Kyriakides; Alberto Costa; Tanja Cufer; Kathy S Albain Journal: J Natl Cancer Inst Date: 2009-08-05 Impact factor: 13.506